New Drug Delivery Systems Market by Route of Administration and Geography - Forecast and Analysis 2022-2026

The new drug delivery systems market share is expected to increase by USD 77.29 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.08%.

This new drug delivery systems market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers new drug delivery systems market segmentation by route of administration (oral drug delivery systems, injectable drug delivery systems, pulmonary drug delivery systems, transdermal drug delivery systems, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The new drug delivery systems market report also offers information on several market vendors, including Abbott Laboratories, Amgen Inc., AstraZeneca Plc, Baxter International Inc., Becton Dickinson and Co., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Gerresheimer AG, Gilead Sciences Inc., Kindeva Drug Delivery L.P., Medtronic Plc, Merck KGaA, Nemera, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., West Pharmaceutical Services Inc., Ypsomed Holding AG, and Antares Pharma Inc. among others.

What will the New Drug Delivery Systems Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the New Drug Delivery Systems Market Size for the Forecast Period and Other Important Statistics

 

New Drug Delivery Systems Market: Key Drivers, Trends, and Challenges

The rising prevalence of chronic diseases is notably driving the new drug delivery systems market growth, although factors such as stringent regulations may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the new drug delivery systems industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key New Drug Delivery Systems Market Driver

One of the key factors driving growth in the new drug delivery systems market is the rising prevalence of chronic diseases. As the various biophysiological factors limit the efficacy of targeted therapy for chronic diseases such as diabetes, cancer, atherosclerosis, myocardial ischemia, asthma, pulmonary tuberculosis, Parkinson's disease, and Alzheimer's disease, many new drug delivery systems are highly in demand to enhance the drug efficacy. For instance, non-long-acting drug delivery systems (LADDS) treat chronic diseases. The technology delivers the drug molecules into target tissues either through systemic circulation or localized injections. Owing to the rising prevalence of diseases and increasing demand for an effective delivery system will boost the market growth in the forecast period.

Key New Drug Delivery Systems Market Trend

The increasing demand for various technologically advanced drug delivery systems with the increase in new diseases and efficient drug therapy is another factor supporting the new drug delivery systems market share growth. For instance, a Bluetooth-enabled drug delivery technology- a nanochannel delivery system(nDS), can be remotely controlled to administer the long-term delivery of drugs. Such new technology can help maintain the appropriate drug concentration in the circulatory system and reduce treatment-monitoring clinical visits and follow-ups with healthcare providers. Similarly, Oxford, England-based Evox has developed DeliverEX drug delivery technology. This technology delivers drugs to organs of interest, including the brain and the central nervous system. Furthermore, in September 2020, Teva Respiratory launched its AirDuo Digihaler and ArmonAir Digihaler digital inhalers in the US. Such innovative drug delivery systems are estimated to drive the market.

Key New Drug Delivery Systems Market Challenge

The stringent regulations will be a major challenge for the new drug delivery systems market during the forecast period. Regulatory authorities carefully study and evaluate drug-related data before approving it. Safety, efficacy, pharmacological data, pharmacodynamic effects, and drug interactions are some of the key factors that are examined by the regulatory bodies. Therefore, a drug failing in any of these criteria is likely to receive a complete response letter (CRL) or may face complete rejection from regulatory agencies. On receiving a CRL, a drug applicant is required to furnish additional data about the drug. This, in turn, may require additional clinical trials and may increase the R and D expenditure of the drug. In some cases, the drug applicants withdraw their applications and discontinue their drug trials. This acts as a strong setback for the company and hinders the market growth.

This new drug delivery systems market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global new drug delivery systems market as a part of the global pharmaceuticals market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the new drug delivery systems market during the forecast period.

Who are the Major New Drug Delivery Systems Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Abbott Laboratories
• Amgen Inc.
• AstraZeneca Plc
• Baxter International Inc.
• Becton Dickinson and Co.
• Boehringer Ingelheim International GmbH
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd.
• Gerresheimer AG
• Gilead Sciences Inc.
• Kindeva Drug Delivery L.P.
• Medtronic Plc
• Merck KGaA
• Nemera
• Pfizer Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.
• West Pharmaceutical Services Inc.
• Ypsomed Holding AG
• Antares Pharma Inc.

 

This statistical study of the new drug delivery systems market encompasses successful business strategies deployed by the key vendors. The new drug delivery systems market is fragmented and the vendors are deploying growth strategies such as focusing on making products that are conducive to the environment and comply with customers requirements, especially in terms of sustainability and pricing to compete in the market.

Product Insights and News

• Baxter International Inc. - The company offers solutions for drug delivery systems that includes in-class infusion pump and comprehensive portfolio of sets and access devices to administer IV fluids and drugs for patients, under the brand name of Baxter.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The new drug delivery systems market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

New Drug Delivery Systems Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the new drug delivery systems market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for New Drug Delivery Systems Market?

For more insights on the market share of various regions Request for a FREE sample now!

41% of the market's growth will originate from North America during the forecast period. The US is the key market for new drug delivery systems in North America. Market growth in this region will be faster than the growth of the market in the European and ROW regions.

The rising prevalence of chronic diseases, the presence of big pharmaceutical and biotechnical vendors, and high investment in the R and D of new drugs will facilitate the new drug delivery systems market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the outbreak of COVID-19 slightly declined the growth of the new drug delivery systems market in North America. s the number of COVID-19 cases increased, various non-urgent healthcare procedures and research studies, including new drug delivery systems, were paused. However, the rise in the number of COVID-19 cases and the introduction of vaccines in Q4 2020 enhanced the demand for new drug delivery systems. 

What are the Revenue-generating Route of Administration Segments in the New Drug Delivery Systems Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The new drug delivery systems market share growth by the oral drug delivery system segment will be significant during the forecast period. The oral route is the most common route for drug administration. Owing to its advantages, including a well-established delivery system, patient-friendly, convenient, cost-effective, and noninvasiveness, it has been the most favored drug delivery system in the pharmaceutical industry. However, various physicochemical, biochemical, metabolic, and biological barriers limit the oral drug bioavailability, thereby hampering the growth of the segment. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the new drug delivery systems market size and actionable market insights on post COVID-19 impact on each segment.

You may be interested in:

Advanced Drug Delivery Systems market - The market share is expected to increase to USD 91.79 billion from 2021 to 2026, at a CAGR of 7.41%.

Injectable Drug Delivery Devices market - The market share is expected to increase by USD 22.29 billion from 2021 to 2026, at a CAGR of 8.48%. 

Drug Delivery Devices market - The market share is expected to increase by USD 77.26 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.28%.

Dental Delivery Systems market - The market share has the potential to grow by USD 100.32 million during 2019-2023. The growth momentum will accelerate throughout the forecast period and the market will grow at a CAGR of almost 5%.

New Drug Delivery Systems Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 6.08%
Market growth 2022-2026	$ 77.29 billion
Market structure	Fragmented
YoY growth (%)	5.35
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 41%
Key consumer countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Abbott Laboratories, Amgen Inc., AstraZeneca Plc, Baxter International Inc., Becton Dickinson and Co., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Gerresheimer AG, Gilead Sciences Inc., Kindeva Drug Delivery L.P., Medtronic Plc, Merck KGaA, Nemera, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., West Pharmaceutical Services Inc., Ypsomed Holding AG, and Antares Pharma Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this New Drug Delivery Systems Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive new drug delivery systems market growth during the next five years
• Precise estimation of the new drug delivery systems market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the new drug delivery systems industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of new drug delivery systems market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch